Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Guidance Production May Be Slowed By New OMB Review Requirement

Executive Summary

White House says all guidances, as well as proposed rules, must be submitted to OMB for a determination whether they are major or minor.
Advertisement

Related Content

Woodcock: Concerns About US FDA's Biosimilars Suffix Policy Detached From Reality
Clinical Trial Reform Is A Focus For CDER's 2019 Guidance Agenda
US FDA Quality Metrics Initiative Continues Moving Forward … Quietly
'Just Say It!' – New Streamlined Guidance Format Coming, FDA's Woodcock Says
US FDA And OMB Should ‘Pause’ Billion-Dollar Quality Metrics Program, Industry Groups Say
AbbVie Looks To White House For Relief From US FDA Naming Guidance
US FDA Likely Not 'Significant', Could Be Mostly Spared From Trump's Regulation-Slashing Order
Senate's Medical Innovation Bill Takes Cures' Shape

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel